#ASCO22: Following back-to-back TIGIT bombs, Roche offers insight into first PhIII trial fail

Roche’s Genentech suffered two consecutive Phase III fails for tiragolumab, the earliest in a series of anti-TIGIT drugs from Big Pharmas hoping to usher in the next generation of immune checkpoint therapies. Today, the Swiss Pharma unveiled specific data on SKYSCRAPER-02, the first trial that flopped, which tested tiragolumab alongside…

...

Click to view original post